Overview

Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II

Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
The investigators wish to determine the time to disease progression for benign neurofibromas treated with Levulan Kerastick topical photosensitizer and red light photodynamic therapy (PDT) in patients with neurofibromatosis type 1 (NF1). The investigators also wish to measure tumor size for control and treatment tumors in order to gain insights into tumor growth rates.
Phase:
Phase 2
Details
Lead Sponsor:
Harry T Whelan, MD
Treatments:
Aminolevulinic Acid